Author

A.R. Phillips

Queen's University Belfast

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Connor N. BrowniD· 2 shared Donna M. SmalliD· 2 shared Emma M. KerriD· 2 shared Matilda Downs· 2 shared Alice T. Browne· 1 shared Alyson SpeediD· 1 shared Carla P. MartinsiD· 1 shared Catherine A. HigginsiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Connor N. BrownORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

FLIP is essential for oncogenic KRAS-driven lung cancer

Claudia Hamilton, Shaun Sharkey, Hajrah A. Khawaja, Matilda Downs, Christopher McLaughlin, Connor N. Brown, Declan F. Doherty, Jennifer Fox, Mihaela Pettigrew, Karl T. Butterworth, A.R. Phillips, Donna M. Small, Timothy Harrison, Catherine A. Higgins, Emma M. Kerr, Daniel B. Longley

This study identifies FLIP as a critical survival factor in KRAS-mutant lung cancers, revealing a KRAS-ERK-FLIP axis that protects against apoptosis and suggests FLIP as a therapeutic target.

bioRxiv · Aug 5, 2026 · PreprintCancer Biology

Mutant KRAS dosage contributes to heterogeneity in lung cancer therapeutic response

Alice T. Browne, Chris McCann, William J. McDaid, Nikita Lewis, Sandhya Sridhar, Gary Joseph Doherty, Deborah Y. Moss, Matilda Downs, Stephen Marry, A.R. Phillips, Connor N. Brown, Alyson Speed, Gemma E. Logan, Gera L. Jellema, James R. Bradford, , Emma M. Kerr

This study shows that mutant KRAS dosage affects therapeutic response in lung cancer, with higher dosages linked to resistance to platinum therapy and sensitivity to pS6K inhibition.

bioRxiv · May 9, 2026 · PreprintCancer Biology